[go: up one dir, main page]

NZ335003A - Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1) - Google Patents

Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1)

Info

Publication number
NZ335003A
NZ335003A NZ335003A NZ33500397A NZ335003A NZ 335003 A NZ335003 A NZ 335003A NZ 335003 A NZ335003 A NZ 335003A NZ 33500397 A NZ33500397 A NZ 33500397A NZ 335003 A NZ335003 A NZ 335003A
Authority
NZ
New Zealand
Prior art keywords
mpif
inhibitory factor
myeloid progenitor
methods
disease states
Prior art date
Application number
NZ335003A
Inventor
Reiner L Gentz
Vikram Patel
Brent L Kreider
Jun Zhang
Michael Antonaccio
Donna Mendrick
Pablo Jimenez
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of NZ335003A publication Critical patent/NZ335003A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptides (previously termed MIP-3 and chemokine beta 8 (CK beta 8 or ckb-8)) and fragments and mutants thereof are provided. The polypeptides may be used in a medicament for regulating hematopoiesis and lymphocyte trafficking, for facilitating wound healing, or for treating conditions such as myelopoietic dysfucntion, psorioasis, cancer, stroke, arthritis or other autoimmune diseases.
NZ335003A 1996-09-30 1997-09-30 Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1) NZ335003A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2730096P 1996-09-30 1996-09-30
US2729996P 1996-09-30 1996-09-30
PCT/US1997/017505 WO1998014582A1 (en) 1996-09-30 1997-09-30 Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (mpif-1), monocyte colony inhibitory factor (m-cif), and macrophage inhibitory factor-4 (mip-4)

Publications (1)

Publication Number Publication Date
NZ335003A true NZ335003A (en) 2000-11-24

Family

ID=26702293

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ335003A NZ335003A (en) 1996-09-30 1997-09-30 Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1)
NZ506135A NZ506135A (en) 1996-09-30 1997-09-30 Monocyte colony inhibitory factor (M-CIF) derivatives and their use in treating sepsis

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ506135A NZ506135A (en) 1996-09-30 1997-09-30 Monocyte colony inhibitory factor (M-CIF) derivatives and their use in treating sepsis

Country Status (8)

Country Link
EP (1) EP0941330A1 (en)
JP (1) JP2001500382A (en)
KR (1) KR20030097607A (en)
CN (1) CN1239510A (en)
AU (1) AU4657697A (en)
CA (1) CA2267193A1 (en)
NZ (2) NZ335003A (en)
WO (1) WO1998014582A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6488925B2 (en) 1993-12-22 2002-12-03 Human Genome Sciences, Inc. Macrophage inflammatory protein-4 (MIP-4) polypeptides
US6001606A (en) * 1994-03-08 1999-12-14 Human Genome Sciences, Inc. Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby
US6811773B1 (en) 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6495129B1 (en) 1994-03-08 2002-12-17 Human Genome Sciences, Inc. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
US6623942B2 (en) 1994-03-08 2003-09-23 Human Genome Sciences, Inc. Macrophage inflammatory protein-4 (MIP-4) polynucleotides
AU775308B2 (en) * 1996-09-30 2004-07-29 Human Genome Sciences, Inc. Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1), monocyte colony inhibitory factor (M-CIF), and macrophage inhibitory factor-4 (MIP-4)
US6632425B1 (en) 1997-03-20 2003-10-14 Human Genome Sciences, Inc. Chemokine compositions
US6495128B1 (en) 1998-11-10 2002-12-17 Human Genome Sciences, Inc. Human chemokine β-7 deletion and substitution proteins
WO2000040610A1 (en) * 1999-01-07 2000-07-13 Takeda Chemical Industries, Ltd. Process for producing activated protein
CA2387545A1 (en) * 1999-10-14 2001-04-19 Human Genome Sciences, Inc. Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (mpif-1)
EP1176200A3 (en) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases or wound healing and their use in indentifying pharmacologically acitve substances
KR100867257B1 (en) * 2001-10-09 2008-11-11 케모센트릭스, 인크. Compositions Useful as Ligands for Formyl Peptide Receptor Like 1 Receptors and Methods of Use thereof
US20030215460A1 (en) * 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
US20030096260A1 (en) * 2001-10-09 2003-05-22 Zhenhua Miao Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
AU2004283853A1 (en) * 2003-10-24 2005-05-06 Tap Pharmaceutical Products Inc. Human chemokine HCC-1 polypeptides to improve stem cell transplantation
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
US20080305494A1 (en) * 2004-03-22 2008-12-11 Carballido Herrera Jose M Chemokine Ccl18 as a Biomarker
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20110039284A1 (en) * 2007-10-22 2011-02-17 Samuel Norbert Breit Methods of prognosis
CN113215085B (en) * 2021-05-07 2024-05-10 澳门大学 Lipid substance additive and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ271756A (en) * 1993-12-22 1998-02-26 Human Genome Sciences Inc Human macrophage inflammatory proteins and coding sequences, their production and use
US20030105293A1 (en) * 1993-12-24 2003-06-05 Wolf-Georg Forssmann Human circulating cytokine cc-1
US5602008A (en) * 1994-11-29 1997-02-11 Incyte Pharmaceuticals, Inc. DNA encoding a liver expressed chemokine
WO1996034891A1 (en) * 1995-05-05 1996-11-07 Human Genome Sciences, Inc. Human chemokine beta-8, chemokine beta-1 and macrophage inflammatory protein-4
HUP9802699A3 (en) * 1995-09-29 2000-09-28 Smithkline Beecham Corp Short forms of chemokine beta-8
EP0871664B1 (en) * 1995-10-24 2004-01-02 Smithkline Beecham Corporation Mobilization of hematopoietic stem cells using a chemokine

Also Published As

Publication number Publication date
CA2267193A1 (en) 1998-04-09
NZ506135A (en) 2002-11-26
CN1239510A (en) 1999-12-22
AU4657697A (en) 1998-04-24
KR20030097607A (en) 2003-12-31
WO1998014582A1 (en) 1998-04-09
JP2001500382A (en) 2001-01-16
EP0941330A1 (en) 1999-09-15

Similar Documents

Publication Publication Date Title
NZ335003A (en) Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1)
EP0735893A4 (en) Alteration of immune response using pan dr-binding peptides
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
GB9416442D0 (en) Therapeutic heterocycles
IL138665A0 (en) Peptide factor
HUS1400034I1 (en) Use of dialkylfumarates for producing pharmaceutical compositions for the treatment autoimmune diseases
ES2091906T3 (en) COMPOSITIONS INCLUDING DERIVATIVES OF AN OMEGA-CONOTOXIN PEPTIDE AND ITS USE IN THE TREATMENT OF NEURONAL DAMAGE RELATED TO ISCHEMIA.
GEP20074095B (en) Analogs of human insulin modified at position 29 of the b chain thereof
MY106272A (en) Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants.
ATE252912T1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FUNCTIONAL DYSPEPSIA AND/OR IRGITABLE BOWEL SYNDROME AND THE USE OF NEW SUBSTANCES IN THIS COMPOSITION
GB2314022B (en) Blending medical composition with sustained medicament releasability and process for preparing the same
GR3035440T3 (en) Therapeutic uses of bpi protein products for human meningococcemia
JPH06329549A (en) Pharmaceutical comprising p40 subunit of interleukin 12
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
CA2068871A1 (en) Non-glycosylated fgf-4 and compositions containing the same
DE69719754D1 (en) THERAPEUTIC USE OF BPI PROTEIN PRODUCTS IN PEOPLE WITH BREEDING THROUGH TRAUMA
CA2123315A1 (en) Therapeutic agents which are antagonists or partial agonists of human interleukin 4
SI1082131T1 (en) Immunoregulator
ATE210149T1 (en) ANTI-INFLAMMATORY COMPOSITION AND METHOD USING DES-TYR DYNORPHINE AND ANALOGUES
GR3034743T3 (en) Growth hormone antagonists.
HU9202075D0 (en) Bcrf1 proteins of gamma-interferon inhibiting effect
ES2128348T3 (en) OBTAINING COMPOSITIONS FOR THE TREATMENT OF ALTERATIONS OF CELL PROLIFERATION.
ES2115055T3 (en) 1-PHENYL-2- (2-PIRIDINYL) ETHYLAMINE ENANTIOMERA FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS.
NO983238L (en) Exodus chemokine materials and methods
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)